J 2024

Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model

HORSKÁ, Kateřina, Jan KUČERA, Eva DRAŽANOVÁ, Gabriela KUZMÍNOVÁ, Petra AMCHOVÁ et. al.

Basic information

Original name

Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model

Name in Czech

Silné synergické účinky dulaglutidu a omezení příjmu potravy v prevenci metabolických nežádoucích účinků vyvolaných olanzapinem u potkana

Authors

HORSKÁ, Kateřina (203 Czech Republic, belonging to the institution), Jan KUČERA (203 Czech Republic, belonging to the institution), Eva DRAŽANOVÁ (203 Czech Republic, belonging to the institution), Gabriela KUZMÍNOVÁ (203 Czech Republic), Petra AMCHOVÁ (203 Czech Republic, belonging to the institution), Mária HRICKOVÁ (703 Slovakia, belonging to the institution), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution) and Silje SKREDE (578 Norway)

Edition

Biomedicine and Pharmacotherapy, ISSY-LES-MOULINEAUX, Elsevier, 2024, 0753-3322

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

France

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.500 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.biopha.2024.116763

UT WoS

001247722500001

Keywords in English

Antipsychotic; Olanzapine; metabolic adverse effects; GLP-1 receptor agonist; Schizophrenia

Tags

14110516

Tags

International impact, Reviewed
Změněno: 1/7/2024 13:46, Mgr. Tereza Miškechová

Abstract

V originále

A combined strategy of dulaglutide and food restriction manifested a massive synergistic benefit. GLP-1RAs represent a promising strategy and deserve thorough future research. Our findings underline the potential importance of lifestyle intervention in addition to GLP-1 RA treatment.

Links

EHP-BFNU-OVNKM-3-048-2020, interní kód MU
Name: Pharmacological reversal of metabolic derrangements induced by antipsychotic treatment in animal models
Investor: Ministry of Finance of the CR, Bilateral Fund
EHP-BFNU-OVNKM-4-078-2022, interní kód MU
Name: Pharmacological reversal of metabolic derangements induced by antipsychotic treatment in animal models: intensification of the collaboration
Investor: Ministry of Finance of the CR, Bilateral Fund
LM2018129, research and development project
Name: Národní infrastruktura pro biologické a medicínské zobrazování Czech-BioImaging
Investor: Ministry of Education, Youth and Sports of the CR
LM2023050, research and development project
Name: Národní infrastruktura pro biologické a medicínské zobrazování
Investor: Ministry of Education, Youth and Sports of the CR, Czech BioImaging: National research infrastructure for biological and medical imaging
MUNI/A/1372/2020, interní kód MU
Name: Preklinický vývoj terapeutických přístupů k redukci nežádoucích metabolických účinků atypických antipsychotik
Investor: Masaryk University
MUNI/A/1580/2023, interní kód MU
Name: Preklinický a klinický výzkum Farmakologického ústavu v oblasti biotrasformace léčiv, behaviorální neuropsychofarmakologie a personalizované farmakoterapie v onkologii
Investor: Masaryk University, Preclinical and clinical research of the Department of Pharmacology in the field of biotransformation of drugs, behavioural neuropsychopharmacology and personalized pharmacotherapy in oncology
Displayed: 6/11/2024 11:12